{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-047890","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2025-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.752482+00:00","generated_at":"2026-05-20T09:51:28.103199+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nektar shareholders approve authorized share increase to 390M and reverse split authorization","bullets":["Proposal 5: authorized common shares increased from 300M to 390M (92.5M for, 55.5M against).","Proposal 6: Board authorized to effect reverse stock split at ratio 1:2 to 1:40 within one year (140M for).","Proposal 2: 2017 Performance Incentive Plan amended to add 6M shares (72.4M for, 28.8M against).","Directors Diana Brainard and R. Scott Greer elected; other directors continue.","Ernst & Young ratified as auditor; say-on-pay advisory resolution passed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-047890","json":"https://secwatch.observer/filing/0001213900-25-047890.json","markdown":"https://secwatch.observer/filing/0001213900-25-047890.md","text":"https://secwatch.observer/filing/0001213900-25-047890.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390025047890/0001213900-25-047890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390025047890/ea0243394-8k_nektar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T09:51:28.103199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}